ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

55 hedge funds and large institutions have $88.8M invested in Arbutus Biopharma in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+7
Holders Change %
+14.58%
% of All Funds
1.38%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
23
Reduced
12
Closed
7
Calls
$620K
Puts
$1.19M
Net Calls
-$567K
Net Calls Change
-$628K

Top Buyers

1
LTFS
1
Ladenburg Thalmann Financial Services
Florida
$13M
2
AC
2
Armistice Capital
New York
$4.75M
3
KPF
3
K2 Principal Fund
Ontario, Canada
$1.09M
4
DCM
4
DAFNA Capital Management
California
$573K
5
OAM
5
Oxford Asset Management
United Kingdom
$392K

Top Sellers

1
HM
1
HealthCor Management
New York
$0
2
AWG
2
Alpha Wave Global
New York
$4.06M
3
Millennium Management
3
Millennium Management
New York
$47K
4
SCM
4
Suffolk Capital Management
New York
$0
5
B
5
Bailard
California
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
IA
51
IFP Advisors
Florida
$1K +$972 +350 +3,500%
SIM
52
Sonora Investment Management
Arizona
$49 – – –
HM
53
HealthCor Management
New York
– -$6.88M -2,000,000 Closed
SCM
54
Suffolk Capital Management
New York
– -$1.08M -314,993 Closed
B
55
Bailard
California
– -$740K -215,000 Closed
PP
56
PDT Partners
New York
– -$78K -22,800 Closed
UBS Group
57
UBS Group
Switzerland
– -$19K -5,500 Closed
BIT
58
BlackRock Institutional Trust
California
– -$13K -3,886 Closed
WIC
59
Woodmont Investment Counsel
Tennessee
– -$3K -800 Closed
1 2
3